Esperion eyes new commercial push for cholesterol-lowering drugs after big FDA label expansion
25 Mar 2024
Drug Approval
Esperion has secured major FDA label expansions for its two cholesterol-lowering drugs, a regulatory milestone that it says opens up a much bigger market and “significantly reduces previously existing prescribing limitations.”
Nexletol and Nexlizet are now approved to prevent heart attacks and cardiovascular procedures in both primary and secondary prevention patients, regardless of statin use. Both pills contain bempedoic acid, Esperion’s key asset, with one being a monotherapy and the other being a combination with another cholesterol-lowering drug, ezetimibe.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.